A synthetic influenza virus vaccine induces a cellular immune response that correlates with reduction in symptomatology and virus shedding in a randomized phase Ib live-virus challenge in humans

Clinical and Vaccine Immunology

Volumn 22, Issue 7, 2015, Pages 828-835

  Pleguezuelos, Olga ^a   Robinson, Stuart ^a   Fernández, Ana ^a   Stoloff, Gregory A ^a   Mann, Alex ^b   Gilbert, Anthony ^b   Balaratnam, Ganesh ^b   Wilkinson, Tom ^c   Lambkin Williams, Rob ^b   Oxford, John ^b   Caparrós Wanderley, Wilson ^a  

^a SEEK   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTYLLEUCYLGLUTAMYLALANYLLEUCYLMETHIONYLGLUTAMYLTRYPTOPHYLLEUCYLLYSYLTHREONYLARGINYLPROPYLISOLEUCYLLEUCYLSERYLPROPYLLEUCYLTHREONYLLYSYLGLYCYLISOLEUCYLLEUCYLGLYCYLPHENYLALANYLVALYLPHENYLALANYLTHREONYLLEUCYLTHREONYLVALYLPROLINE; ASPARTYLLEUCYLISOLEUCYLPHENYLALANYLLEUCYLALANYLARGINYLSERYLALANYLLEUCYLISOLEUCYLLEUCYLARGINYLGLYCYLSERYLVALYLALANYLHISTIDINYLLYSYLSERYLCYSTEINE; GAMMA INTERFERON; INFLUENZA VACCINE; ISOLEUCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLHISTIDINYLLEUCYLISOLEUCYLLEUCYLTRYPTOPHYLISOLEUCYLLEUCYLASPARTYLARGINYLLEUCYLPHENYLALANYLPHENYLALANYLLYSYLCYSTEINYLISOLEUCYLTYROSYLARGINYLLEUCYLPHENYLALANINE; PLACEBO; PROPYLGLYCYLISOLEUCYLALANYLASPARTYLISOLEUCYLGLUTAMYLASPARTYLLEUCYLTHREONYLLEUCYLLEUCYLALANYLARGINYLSERYLMETHIONYLVALYLVALYLVALYLARGININE; SYNTHETIC INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; HEMAGGLUTINATION INHIBITION TEST; HUMAN; INFECTION PREVENTION; INFLUENZA A (H3N2); INFLUENZA VIRUS A H3N2; INJECTION SITE PAIN; INJECTION SITE PRURITUS; MALE; MYALGIA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCORING SYSTEM; SWELLING; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRUS LOAD; VIRUS SHEDDING; ADOLESCENT; IMMUNOLOGY; INFLUENZA, HUMAN; MIDDLE AGED; MONONUCLEAR CELL; NORMAL HUMAN; PATHOLOGY; SECRETION (PROCESS); VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; HEALTHY VOLUNTEERS; HUMANS; IMMUNITY, CELLULAR; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PLACEBOS; VIRAL LOAD; VIRUS SHEDDING; YOUNG ADULT;

EID: 84936866203     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00098-15     Document Type: Article

References (32)

1. Carrat F, Flahault A. 2007. Influenza vaccine: the challenge of antigenic drift. Vaccine 25:6852-6862. http://dx.doi.org/10.1016/j.vaccine.2007.07.027.
2. Gerdil C. 2003. The annual production cycle for influenza vaccine. Vaccine 21:1776-1779. http://dx.doi.org/10.1016/S0264-410X(03)00071-9.
3. Osterholm MT, Kelley NS, Sommer A, Belongia EA. 2012. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12:36-44. http://dx.doi.org/10.1016/S1473-3099(11) 70295-X.
4. Polosukhin VV, Cates JM, Lawson WE, Zaynagetdinov R, Milstone AP, Massion PP, Ocak S, Ware LB, Lee JW, Bowler RP, Kononov AV, Randell SH, Blackwell TS. 2011. Bronchial secretory immunoglobulin A deficiency correlates with airway inflammation and progression of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 184: 317-327. http://dx.doi.org/10.1164/rccm.201010-1629OC.
5. Lambert LC, Fauci AS. 2010. Influenza vaccines for the future. N Engl J Med 363:2036-2044. http://dx.doi.org/10.1056/NEJMra1002842.
6. Kreijtz JH, Fouchier RA, Rimmelzwaan GF. 2011. Immune responses to influenza virus infection. Virus Res 162:19-30. http://dx.doi.org/10.1016/j.virusres.2011.09.022.
7. Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, Hamill M, Peng Y, Blais ME, Duncan CJ, Sheehy SH, Havelock T, Faust SN, Williams RL, Gilbert A, Oxford J, Dong T, Hill AV, Gilbert SC. 2012. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 55:19-25. http://dx.doi.org/10.1093/cid/cis327.
8. Stoloff GA, Caparrós-Wanderley W. 2007. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Eur J Immunol 37:2441-2449. http://dx.doi.org/10.1002/eji.200737254.
9. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745-1749. http://dx.doi.org/10.1126/science.8456302.
10. Graham MB, Braciale TJ. 1997. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J Exp Med 186: 2063-2068.
11. Christensen JP, Doherty PC, Branum KC, Riberdy JM. 2000. Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8(+) T-cell memory. J Virol 74:11690-11696. http://dx.doi.org/10.1128/JVI.74.24.11690-11696.2000.
12. Pleguezuelos O, Robinson S, Stoloff GA, Caparrós-Wanderley W. 2012. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled phase I trial. Vaccine 30: 4655-4660. http://dx.doi.org/10.1016/j.vaccine.2012.04.089.
13. Shibaki A, Katz SI. 2002. Induction of skewed Th1/Th2 T-cell differentiation via subcutaneous immunization with Freund?s adjuvant. Exp Dermatol 11:126-134. http://dx.doi.org/10.1034/j.1600-0625.2002.110204.x.
14. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, Staples KJ, Dong T, Douek DC, McMichael AJ, Xu XN. 2012. Preexisting influenzaspecific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 18:274-280. http://dx.doi.org/10.1038/nm.2612.
15. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. 1998. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J Clin Invest 101:643-649.
16. World Health Organization Global Surveillance Network. 2011. Manual for the laboratory diagnosis and virological surveillance of influenza. http://whqlibdoc.who.int/publications/2011/9789241548090-eng.pdf.
17. Siegrist CA. 2012. Vaccine immunology, p 17-36. In Plotkin S, Orenstein W, Offit P (ed), Vaccines, 6th ed. Elsevier, Amsterdam, Netherlands.
18. Boffito M, Fox J, Bowman C, Fisher M, Orkin C, Wilkins E, Jackson A, Pleguezuelos O, Robinson S, Stoloff GA, Caparrós-Wanderley W. 2013. Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, placebo-controlled phase Ib human trial. Vaccine 31:5680-5686. http://dx.doi.org/10.1016/j.vaccine.2013.09.057.
19. Graham BS, McElrath MJ, Keefer MC, Rybczyk K, Berger D, Weinhold KJ, Ottinger J, Ferarri G, Montefiori DC, Stablein D, Smith C, Ginsberg R, Eldridge J, Duerr A, Fast P, Haynes BF, AIDS Vaccine Evaluation Group. 2010. Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS One 5:e11995. http://dx.doi.org/10.1371/journal.pone.0011995.
20. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP. 2008. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 3:e2636. http://dx.doi.org/10.1371/journal.pone.0002636.
21. Atkinson W, Wolfe S, Hamborsky J (ed). 2012. Epidemiology and prevention of vaccine-preventable diseases, 12th ed. Appendix D: vaccine administration guidelines. Centers for Disease Control and Prevention, Atlanta, GA.
22. Tanguay S, Killion JJ. 1994. Direct comparison of ELISPOT and ELISAbased assays for detection of individual cytokine-secreting cells. Lymphokine Cytokine Res 13:259-263.
23. Favre N, Bordmann G, Rudin W. 1997. Comparison of cytokine measurements using ELISA, ELISPOT and semi-quantitative RT-PCR. J Immunol Methods 204:57-66. http://dx.doi.org/10.1016/S0022-1759(97) 00033-1.
24. Sarawar SR, Sangster M, Coffman RL, Doherty PC. 1994. Administration of anti-IFN-gamma antibody to beta 2-microglobulin-deficient mice delays influenza virus clearance but does not switch the response to a T helper cell 2 phenotype. J Immunol 153:1246-1253.
25. Ulmer JB, Fu TM, Deck RR, Friedman A, Guan L, DeWitt C, Liu X, Wang S, Liu MA, Donnelly JJ, Caulfield MJ. 1998. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 72:5648-5653.
26. Katial RK, Sachanandani D, Pinney C, Lieberman MM. 1998. Cytokine production in cell culture by peripheral blood mononuclear cells from immunocompetent hosts. Clin Diagn Lab Immunol 5:78-81.
27. Li Q, Furman SA, Bradford CR, Chang AE. 1999. Expanded tumorreactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation. Clin Cancer Res 5:461-469.
28. Oukka M, Manuguerra JC, Livaditis N, Tourdot S, Riche N, Vergnon I, Cordopatis P, Kosmatopoulos K. 1996. Protection against lethal viral infection by vaccination with non-immunodominant peptides. J Immunol 157:3039-3045.
29. Cole GA, Hogg TL, Coppola MA, Woodland DL. 1997. Efficient priming of CD8+ memory T cells specific for a subdominant epitope following Sendai virus infection. J Immunol 158:4301-4309.
30. McMichael AJ, Gotch FM, Noble GR, Beare PA. 1983. Cytotoxic T-cell immunity to influenza. N Engl J Med 309:13-17. http://dx.doi.org/10.1056/NEJM198307073090103.
31. Hillaire ML, van Trierum SE, Kreijtz JH, Bodewes R, Geelhoed-Mieras MM, Nieuwkoop NJ, Fouchier RA, Kuiken T, Osterhaus AD, Rimmelzwaan GF. 2011. Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. J Gen Virol 92(Pt 10):2339-2349. http://dx.doi.org/10.1099/vir.0.033076-0.
32. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, Bean T, Barclay W, Deeks JJ, Lalvani A. 2013. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 19:1305-1312. http://dx.doi.org/10.1038/nm.3350.